RT Journal Article
SR Electronic
T1 High prevalence of deep venous thrombosis in non-severe COVID-19 patients hospitalized for a neurovascular disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.03.20187344
DO 10.1101/2020.09.03.20187344
A1 Olivier Rouyer
A1 Irène Nora Pierre-Paul
A1 Amadou Talibe Balde
A1 Damaris Jupiter
A1 Daniela Bindila
A1 Bernard Geny
A1 Valérie Wolff
YR 2020
UL http://medrxiv.org/content/early/2020/09/05/2020.09.03.20187344.abstract
AB Introduction Severe SARS-CoV-2 infection, responsible for COVID-19, is accompanied by venous thromboembolic events particularly in intensive care unit. In non-severe COVID-19 patients affected by neurovascular diseases, the prevalence of deep venous thrombosis (DVT) is unknown. The aim of or study was to report data obtained after systematic Doppler ultrasound scanning (DUS) of lower limbs in such patients.Methods Between March 20 and May 2, 2020, consecutive patients with neurovascular diseases with non-severe COVID-19 were investigated with a systematic bedside DUS.Results Thirteen patients were enrolled including 10 acute ischemic strokes, one transient ischemic attack, one cerebral venous thrombosis and one haemorrhagic stroke. At admission the median National Institute of Health Stroke Scale (NIHSS) was of 6 (IQR, 0–20). We found a prevalence of 38.5% of asymptomatic calves’ DVT (n = 5) during the first week after admission despite thromboprophylaxis. Among them, one patient had a symptomatic pulmonary embolism. Two patients died during hospitalization but the outcome was favourable in the others with a discharge median NIHSS of 1 (IQR, 0–11).Discussion/Conclusion Despite thromboprophylaxis, systematic bedside DUS showed a high prevalence of 38.5% of DVT in non-severe COVID-19 patients with neurovascular diseases. Therefore, we suggest that this non-invasive investigation should be performed in all patients of this category.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialclinicaltrials.gov.: unique identifier: NCT04452422).Funding StatementThis work support no fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The approval for this study was obtained from the local ethics committee of the Strasbourg University Hospital (reference CE-2020-111)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesthe data mentioned in the manuscript are available on request to the corresponding author.